

# A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13

\*Minyun Zhou,<sup>1,2</sup> \*Xianchi Dong,<sup>1,2</sup> Carsten Baldauf,<sup>3</sup> Hua Chen,<sup>4</sup> Yanfeng Zhou,<sup>5</sup> Timothy A. Springer,<sup>5</sup> Xinping Luo,<sup>4</sup> Chen Zhong,<sup>1</sup> Frauke Gräter,<sup>3,6</sup> and Jianping Ding<sup>1</sup>

<sup>1</sup>State Key Laboratory of Molecular Biology and Research Center for Structural Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and <sup>2</sup>Graduate School of Chinese Academy of Sciences, Shanghai, China; <sup>3</sup>Key Laboratory of Computational Biology of Chinese Academy of Sciences, Chinese Academy of Sciences and German Max Planck Society Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China; <sup>4</sup>Huashan Hospital, Fudan Medical School, Shanghai, China; <sup>5</sup>Immune Disease Institute, Children's Hospital Boston and Department of Pathology, Harvard Medical School, Boston, MA; and <sup>6</sup>Heidelberg Institute for Theoretical Studies, Heidelberg, Germany

**The proteolysis of VWF by ADAMTS13 is an essential step in the regulation of its hemostatic and thrombogenic potential. The cleavage occurs at strand  $\beta 4$  in the structural core of the A2 domain of VWF, so unfolding of the A2 domain is a prerequisite for cleavage. In the present study, we present the crystal structure of an engineered A2 domain that exhibits a significant difference in the  $\alpha 3$ - $\beta 4$  loop compared with the previ-**

**ously reported structure of wild-type A2. Intriguingly, a metal ion was detected at a site formed mainly by the C-terminal region of the  $\alpha 3$ - $\beta 4$  loop that was later identified as  $\text{Ca}^{2+}$  after various biophysical and biochemical studies. Force-probe molecular dynamic simulations of a modeled structure of the wild-type A2 featuring the discovered  $\text{Ca}^{2+}$ -binding site revealed that an increase in force was needed to unfold strand  $\beta 4$  when**

**$\text{Ca}^{2+}$  was bound. Cleavage assays consistently demonstrated that  $\text{Ca}^{2+}$  binding stabilized the A2 domain and impeded its unfolding, and consequently protected it from cleavage by ADAMTS13. We have revealed a novel  $\text{Ca}^{2+}$ -binding site at the A2 domain of VWF and demonstrated a relationship between  $\text{Ca}^{2+}$  and force in the regulation of VWF and primary hemostasis. (*Blood*. 2011; 117(17):4623-4631)**

## Introduction

VWF plays an important role in primary hemostasis by mediating platelet adhesion. VWF is stored in endothelial Weibel-Palade bodies and platelet  $\alpha$ -granules as glycosylated multimers consisting of the largest multimeric species, ultra-large VWF.<sup>1-4</sup> Upon stimulation, the VWF multimers are released into the circulating blood or subendothelial matrix. Within 2 hours after release into the vessel, the secreted ultra-large VWF multimers are converted by ADAMTS13 proteolysis into smaller multimers ranging from 500-20 000 kDa.<sup>5-8</sup> The cleavage site for ADAMTS13 resides at the Tyr1605-Met1606 bond in the A2 domain,<sup>1,9</sup> a cryptic site buried in the central  $\beta$ -strand in the intact, folded A2 domain that is inaccessible to ADAMTS13.<sup>10</sup>

More than a decade ago, it was observed that shear stress promotes the process of VWF proteolysis.<sup>11</sup> Since that time, a large body of evidence has supported the notions that the conformation of VWF fibers is altered by shear stress<sup>12</sup> and that unfolding of VWF by shear stress leads to enhanced susceptibility of the VWF to ADAMTS13 proteolysis.<sup>13-15</sup> Because the hemostatic potential of VWF greatly increases with its length, cleavage by ADAMTS13 provides an important regulatory mechanism for primary hemostasis. The cleavage process is precisely regulated in vivo, and dysfunction of this regulation can lead to severe consequences. For example, mutations in VWF that cause increased susceptibility of VWF to ADAMTS13 lead to a shift of the multimer distribution to smaller forms with less hemostatic potential, resulting in continuous bleeding diseases known as VWD.<sup>16,17</sup> Most mutations in the

A2 domain that are associated with VWD type 2A, the common qualitative defect of VWD, result in enhanced proteolytic susceptibility.<sup>18</sup>

Recently, it was clearly shown that unfolding of A2 is required for its cleavage by ADAMTS13, and an intermediate state exists with unfolding of the C-terminal region up to and including the  $\beta 4$  strand where the cleavage site is located.<sup>19</sup> Further information about the stepwise unfolding of A2 under tensile stress and the consequent exposure of the ADAMTS13 cleavage site were revealed by simulations of force-probe molecular dynamics (MD).<sup>20</sup> To further understand the molecular mechanism underlying the shear force-induced cleavage of the VWF A2 domain by ADAMTS13, we carried out structural and functional studies of the A2 domain. We constructed an engineered A2 domain (N1493C/C1670S, ssA2) by introducing an A1/A3-like disulfide bond<sup>20</sup> that allowed us to perform further structural studies. While we solved the crystal structure of the engineered A2 domain, Zhang et al reported the crystal structure of a wild-type A2 (wtA2) domain, which provided structural insights into the mechanism of its shear force sensor function.<sup>21</sup> Compared with the wtA2 domain, our ssA2 structure reveals a novel  $\text{Ca}^{2+}$ -binding site on the  $\alpha 3$ - $\beta 4$  loop that is absent in the wtA2 structure. To investigate the potential functional role of  $\text{Ca}^{2+}$  binding in the shear force-dependent cleavage of the VWF A2 domain by ADAMTS13, we performed MD simulations, mutagenesis studies, and in vitro biochemical assays. Our results show that the binding of  $\text{Ca}^{2+}$

Submitted November 25, 2010; accepted February 17, 2011. Prepublished online as *Blood* First Edition paper, March 8, 2011; DOI 10.1182/blood-2010-11-321596.

\*M.Z. and X.D. contributed equally to this study.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2011 by The American Society of Hematology

**Table 1. Statistics of X-ray diffraction data and structure refinement**

	ssA2	ssA2-D1596A	ssA2-N1602A	ssA2-D1596A/N1602A
PDB code	3PPV	3PPW	3PPX	3PPY
<b>Diffraction data</b>				
Space group	<i>P6<sub>5</sub></i>	<i>P6<sub>5</sub></i>	<i>P6<sub>5</sub></i>	<i>P6<sub>5</sub></i>
Cell parameters				
<i>a</i> = <i>b/c</i> , Å	69.8/73.6	72.1/76.3	72.1/76.3	72.5/76.3
Resolution range, Å	50.0-1.9	50.0-1.9	50.0-1.9	50.0-2.0
	(1.97-1.90)*	(1.97-1.90)	(1.97-1.90)	(2.07-2.00)
Observed reflections, no.	132 324	72 418	95 704	101,783
Unique reflections ( <i>I</i> / $\sigma$ ( <i>I</i> ) > 0), no.	15 647	17 621	17 507	15 351
Average redundancy	8.5 (4.9)	4.1 (3.1)	5.5 (4.2)	6.6 (4.4)
<i>I</i> / $\sigma$ ( <i>I</i> )	20.9 (2.5)	23.1 (6.7)	16.8 (3.6)	17.3 (3.4)
Completeness, %	97.0 (87.5)	99.0 (97.8)	98.2 (82.5)	99.3 (96.6)
<i>R</i> <sub>merge</sub> , %†	10.3 (46.9)	5.8 (27.0)	12.2 (43.6)	12.3 (40.9)
<b>Refinement and structure model</b>				
Reflections ( <i>F</i> <sub>o</sub> > 0 $\sigma$ ( <i>F</i> <sub>o</sub> ))	15 645	17 597	17 506	15 335
Working set	14 864	16 707	16 615	14 552
Free R set	781	890	891	783
<i>R</i> factor, %‡	20.1 (26.5)	20.4 (29.1)	20.6 (27.0)	20.1 (23.6)
Free <i>R</i> factor, %‡	23.1 (36.9)	22.6 (33.7)	23.7 (28.0)	23.2 (24.6)
Subunits/ASU	1	1	1	1
Average <i>B</i> factor, Å <sup>2</sup>				
Protein main-chain atoms, Å <sup>2</sup>	23.0	15.4	16.7	16.8
Protein side-chain atoms, Å <sup>2</sup>	24.0	14.4	16.3	16.8
RMSD bond lengths, Å	0.006	0.006	0.006	0.006
RMSD bond angles, degrees	1.1	1.1	1.1	1.1
Luzzati positional error, Å	0.228	0.237	0.227	0.222
Ramachandran plot, %				
Most favored regions, %	91.1	93.0	93.0	92.5
Allowed regions, %	8.3	6.4	6.4	6.9
Generously allowed regions, %	0.6	0.6	0.6	0.6

RMSD indicates root mean square deviation; and ASU, asymmetric unit.

\*Numbers in parentheses refer to the highest-resolution shell.

† $R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$

‡ $R \text{ factor} = \frac{\sum \|F_o - F_c\|}{\sum |F_o|}$

stabilizes the A2 domain and impedes its unfolding, thus decreasing the susceptibility of the A2 domain to ADAMTS13 proteolysis. Our structural and biochemical data provide new insights into the regulation of VWF cleavage by ADAMTS13 in hemostasis and thrombosis.

## Methods

### Cloning, expression, and purification of VWF A2 domain

The gene fragment of the VWF A2 domain (residues Leu1487-Gly1674) was amplified from the cDNA of HEK293T cells and inserted into pET22b (Novagen). An engineered A2 domain (ssA2) that contains the N1493C and C1670S mutations was generated to introduce a disulfide bond that links the N- and C-termini of the A2 domain in a manner analogous to that in the VWF A1 and A3 domains.<sup>20</sup>

The ssA2 protein and its mutants were expressed in *E coli* BL21 (DE3) CodonPlus cells. The proteins were purified with nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography followed by gel filtration. The target proteins were concentrated to 15 mg/mL in buffer A (20mM Tris-HCl, pH 8.0, 300mM NaCl, 10% glycerol, and 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) for crystallization. For inductively coupled plasma atomic emission spectroscopy analysis, the purified ssA2 protein was further dialyzed against buffer B (3mM Tris-HCl, pH 8.0).

For cleavage assays, the wild-type and mutant wtA2 proteins were expressed in HEK293S GNT1<sup>-</sup> cells, as described previously.<sup>21</sup> The target proteins were purified by Ni-NTA affinity chromatography. VWF73 (residues Asp1596-Arg1668) was shown to be the minimal substrate for

ADAMTS13.<sup>22</sup> The VWF73 gene fragment with a C-terminal hexahistidine tag was inserted into pGEX4T1. The wild-type and mutant glutathione *S*-transferase (GST)-VWF73 proteins were expressed in *E coli* BL21 (DE3) CodonPlus cells and purified by Ni-NTA followed by GST affinity chromatography. The purified wtA2 and VWF73 proteins were dialyzed against buffer C (50mM HEPES, pH 7.4, and 150mM NaCl) for cleavage assays.

### Crystallization, diffraction data collection, and structure determination and refinement

Crystallization experiments were carried out at 4°C using the hanging drop vapor diffusion method. The crystals of ssA2 and its mutants were grown in drops containing equal volumes of the protein solution and the crystallization solution (0.1M sodium citrate, pH 5.2, and 1.6M [NH<sub>4</sub>]<sub>2</sub>SO<sub>4</sub>). The crystals were cryoprotected with the reservoir solution supplemented with 25% glycerol and then flash-frozen in liquid nitrogen. X-ray diffraction data were collected at -173°C at beam-line 17U of the Shanghai Synchrotron Radiation Facility (Shanghai, China) at a wavelength of 1.0000 Å using a MAR225 detector, and were processed using the HKL2000 (Version 0.98.698x, HKL Research Inc) software suite.<sup>23</sup> Diffraction data statistics are summarized in Table 1.

The ssA2 structure was determined using the molecular replacement method with PHASER (Version 2.1.4; Phaser Scientific Software LLC)<sup>24</sup> using the VWF A3 structure (Research Collaboratory for Structural Bioinformatics [RCSB] Protein Data Bank [PDB] code 1A03)<sup>25</sup> as a search model. The initial structure refinement was carried out with CNS (Version 1.2)<sup>26</sup> and the manual model building was performed with COOT (Version 8.4.1).<sup>27</sup> In the initial difference Fourier maps, it was evident that a disulfide

bond formed between Cys1493 and Cys1669, and strong electron density corresponding to a metal ion was detected near the  $\alpha$ 3- $\beta$ 4 loop (the nomenclature of the secondary structures of ssA2 adopts that of wtA2 by Zhang et al<sup>21</sup>), which was further identified as a Ca<sup>2+</sup> ion (see "Results"). The final structure refinement was performed with REFMAC5.<sup>28</sup> The structures of the ssA2 mutants were determined using the ssA2 structure as the starting model. The statistics of the structure refinement and the final structure models are listed in Table 1.

### Force-probe MD simulations

Molecular modeling and in silico mutagenesis were performed with MOE (2009.10, Chemical Computing Group CCG). A wtA2 model (residues 1495-1671) was constructed based on the ssA2 structure by mutations of Cys1493 back to Asn and Ser1670 back to Cys and subsequent generation of a vicinal disulfide bridge between Cys1669 and Cys1670. The assigned Ca<sup>2+</sup> ion was kept or replaced with a water molecule.

All MD simulations and analyses were carried out with the Gromacs suite (version 3.3.3)<sup>29</sup> and the OPLS all-atom force field.<sup>30</sup> For the equilibrium MD simulations, the protein was solvated in dodecahedral boxes with at least 5500 TIP4p water molecules<sup>31</sup> under periodic boundary conditions. The typical protonation states at pH 7 were chosen for ionizable groups of the protein and the necessary amount of counter-ions (Cl<sup>-</sup> and Na<sup>+</sup>) were added to ensure a neutral system of physiologic ion strength. A temperature of 27°C and a pressure of 1 bar were assumed. The wtA2 models were simulated each for at least 20 nanoseconds and up to 40 nanoseconds.

For the force-probe MD simulations, the systems were solvated in 19-nm-long rectangular boxes each containing approximately 20 000 water molecules. Harmonic springs were attached to the terminal C $\alpha$  atoms with spring constants of 500 kJ/(mol/nm<sup>2</sup>) and then moved away from each other with a velocity of 1.25 nm/ns so that each of the simulations spanned approximately 26 nanoseconds. To keep the system size (ie, the simulation box size) reasonable, the force-probe MD simulations were split into 2 parts. In the beginning, the whole wtA2 domain (residues 1495-1671) was simulated until unfolding of the C-terminal secondary structure elements  $\alpha$ 6,  $\beta$ 6, and  $\alpha$ 5 was completed. Subsequently, the unfolded region (residues 1634-1671) was removed and the force-probe MD simulations were continued with the truncated fragment.

### A2 cleavage assays

The in vitro cleavage assays of the wtA2 and GST-VWF73 proteins included preincubation of the proteins with urea at different concentrations of Ca<sup>2+</sup> (step I), followed by administration of ADAMTS13 for the A2 cleavage (step II). In step I, 200  $\mu$ g/mL of A2 protein in the assay buffer (50mM HEPES, pH 7.5, 150mM NaCl, 50 $\mu$ M ZnCl<sub>2</sub>, and 0.1% BSA) was incubated at 37°C for 2 hours with different concentrations of urea (1.92M, 2.56M, 3.20M, and 3.84M) and Ca<sup>2+</sup> (0mM, 2.5mM, and 5.0mM). For the VWF73 substrates, urea was not added. In step II, for each reaction, 5  $\mu$ L of the preincubated A2 protein in the assay buffer and 5  $\mu$ L of 20  $\mu$ g/mL ADAMTS13 (R&D Systems) in 50mM Tris-HCl (pH 8.5) were mixed and then incubated at 37°C for 1 hour with or without adjustment of the Ca<sup>2+</sup> concentration. In some assays, step I was omitted, and 5  $\mu$ L of the ssA2 protein in the assay buffer containing different concentrations of urea and Ca<sup>2+</sup> were incubated with 5  $\mu$ L of the diluted ADAMTS13 at 37°C for 3 hours. The cleaved C-terminal fragments of the A2 proteins and the intact A2 proteins were detected using Western blotting with the specific antibodies anti-A2C (R&D Systems) and anti-His (Tiangen Biotech), respectively. All experiments were performed at least 3 times.

## Results

### Crystal structure of VWF A2 domain

The wtA2 protein expressed with the *E coli* expression system was insoluble, and the refolded wtA2 did not show homogeneity and

failed to produce any crystal. Thus, an engineered A2 domain (ssA2) was generated by introducing 2 mutations (N1493C and C1670S) to form a disulfide bond between the N- and C-termini analogous to that in the VWF A1 and A3 domains,<sup>20</sup> which allowed further structural studies.


The crystals of ssA2 belong to space group *P*6<sub>5</sub> (Table 1), which is different from that of wtA2 (*P*2<sub>1</sub>).<sup>21</sup> The asymmetrical unit contains one ssA2 molecule, corresponding to a Matthews coefficient of 2.3  $\text{\AA}^3/\text{Da}$  and a solvent content of 46%. The ssA2 structure was determined at a 1.9  $\text{\AA}$  resolution, and was refined to an *R* factor of 20.1% and a free *R* factor of 23.1% (Table 1). The ssA2 structure assumes a typical Rossmann fold and is very similar to the wtA2 structure with a root mean square deviation of 1.0  $\text{\AA}$  for all C $\alpha$  atoms (Figure 1A-B). As observed in the wtA2 structure (PDB code 3GXB),<sup>21</sup> Pro1645 takes a *cis* configuration.

### A novel Ca<sup>2+</sup>-binding site

The only major conformational difference between the ssA2 and wtA2 structures occurs in the region (residues 1591-1602) connecting  $\alpha$ 3 and  $\beta$ 4. This region forms a short  $_3$ 10 helix in wtA2 but a loop in ssA2 (Figure 1B). The disulfide bond between Cys1493 and Cys1669 does not cause any notable conformational change in the nearby regions and therefore is unrelated to the observed conformational change of the  $\alpha$ 3- $\beta$ 4 loop (supplemental Figure 1A, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). Intriguingly, a metal ion is bound at this loop with evident electron density (supplemental Figure 1B). It is coordinated in an octahedral geometry by 6 ligands: the main-chain carbonyls of Arg1597 (2.3  $\text{\AA}$ ) and Ala1600 (2.3  $\text{\AA}$ ), the side-chain carboxyl of Asp1498 (2.3  $\text{\AA}$ ) and Asp1596 (2.4  $\text{\AA}$ ), the side-chain carbonyl of Asn1602 (2.3  $\text{\AA}$ ), and a water molecule (2.4  $\text{\AA}$ ) (Figure 1C). The metal ion might be Ca<sup>2+</sup> because of the typical Ca<sup>2+</sup>-binding geometry.<sup>32</sup> At the equivalent site of wtA2, a molecule was also observed with 6 coordinating ligands (Figure 1D), which was assigned as a water molecule (see "Discussion").

To identify the type of the metal ion, we performed inductively coupled plasma atomic emission spectroscopy analyses of the protein solution and the buffer. The results showed a higher content of Ca<sup>2+</sup> ions (0.0042% vs 0.0011%) and Zn<sup>2+</sup> ions (0.0013% vs 0.0002%) in the protein solution than in the buffer alone (Table 2), suggesting that the bound metal ion might have been Ca<sup>2+</sup> or Zn<sup>2+</sup>. For further verification, we collected anomalous dispersion data at the peak wavelengths of Zn<sup>2+</sup> (1.28  $\text{\AA}$ ) and Ni<sup>2+</sup> (1.49  $\text{\AA}$ ) and the most commonly used wavelength for Ca<sup>2+</sup> (1.77  $\text{\AA}$ ), respectively. Evident anomalous signal was only detected at the metal-binding site at the wavelength of 1.77  $\text{\AA}$  (supplemental Figure 2A), indicating that the bound metal ion was Ca<sup>2+</sup> rather than Zn<sup>2+</sup> or Ni<sup>2+</sup>. Because no Ca<sup>2+</sup> and Zn<sup>2+</sup> ions were added in the crystallization solution, it is most likely that the bound Ca<sup>2+</sup> ion was copurified with the protein from the expression system and that the trace of Zn<sup>2+</sup> ions in the protein solution were nonspecifically bound to the C-terminal hexahistidine tag.

To investigate whether mutations of residues at the metal-binding site would impede Ca<sup>2+</sup> binding, the crystal structures of the D1596A, N1602A, and D1596A/N1602A mutants of ssA2 were determined. In all of these mutant structures, the region encompassing residues 1591-1602 still assumed a loop conformation similar to that in the intact ssA2, and there was evident electron density at the metal-binding site corresponding to a bound metal ion. However, because of the loss of ligand(s), the coordination geometries of the metal ion were distorted with a 5-coordination



**Figure 1. Structure of ssA2.** (A) Two views of the overall structure of ssA2. The A2 domain forms a compact structure, with the Tyr1605-Met1606 cleavage site being buried. Residues Tyr1605 and Met1606 are shown as ball-and-stick models and are colored in blue. The region of ssA2 N-terminal to the cleavage site is colored in green and that C-terminal to the site in salmon. The bound  $\text{Ca}^{2+}$  ion is shown as a golden sphere. The secondary structure elements of ssA2 are labeled. (B) Structural comparison of ssA2 (cyan) and wtA2 (pink; PDB code 3GX8). The major structural difference occurs in the  $\alpha 3$ - $\beta 4$  region. The  $\alpha 3$ - $\beta 4$  region is labeled and enclosed in a circle. (C) The  $\text{Ca}^{2+}$ -binding site of ssA2. The surrounding residues are shown as ball-and-stick models. The coordination bonds between  $\text{Ca}^{2+}$  and the ligands are indicated with dashed lines and the bond lengths ( $\text{\AA}$ ) are marked. (D-G) The equivalent sites in wtA2 and the ssA2 mutants. The wtA2 protein (D) is colored in magenta, and those of the D1596A (E), N1602A (F), and D1596A/N1602A (G) mutants of ssA2 are colored in white, blue, and orange, respectively. In each of these structures, a molecule (wheat) is bound at this site, although in a geometry different from that of ssA2.

geometry in the D1596A and N1602A mutants and a 4-coordination geometry in the D1596A/N1602A mutant (Figure 1E-G). The coordination bond lengths were much longer than those in the ssA2 structure but similar to those in the wtA2 structure (Figure 1E-G

and supplemental Table 1). In addition, we collected anomalous dispersion data at the wavelength of 1.77  $\text{\AA}$  for all of these mutants but no anomalous signal was observed, indicating that the bound ions in the mutants were unlikely to be  $\text{Ca}^{2+}$ . These results suggest

**Table 2. Inductively coupled plasma atomic emission spectroscopy results**

Metal	Protein solution, %	Buffer, %
Ca	0.0042	0.0011
Zn	0.0013	0.0002
Cu	0.0002	0.0002

that mutations of Asp1596 and Asn1602 impair the ability of ssA2 to bind  $\text{Ca}^{2+}$ .


### $\text{Ca}^{2+}$ binding impedes the unfolding of the A2 domain

To explore the functional role of  $\text{Ca}^{2+}$  binding, we conducted simulation studies to examine the effect of  $\text{Ca}^{2+}$  binding on the force required for the unfolding of the A2 domain. Based on the ssA2 structure, we constructed a wtA2 model by removing the engineered disulfide bond and then generating a vicinal disulfide bridge between Cys1669 and Cys1670, as observed in the wtA2 structure. The derived wtA2 model was stable in equilibrium MD simulations, the  $\text{Ca}^{2+}$ -binding site remained intact, and the ion stayed in place, again indicating that the observed loop conformation of the  $\alpha$ 3- $\beta$ 4 region and  $\text{Ca}^{2+}$  binding were unrelated to the engineered disulfide bond. This model was then subjected to force-probe MD simulations with or without  $\text{Ca}^{2+}$  being bound.


The force-probe MD simulation results of the wtA2 model were compared with those of the wtA2 structure.<sup>20</sup> For the initial

unfolding of the C-terminal part ( $\alpha$ 6,  $\beta$ 6, and  $\alpha$ 5), the trajectories of the wtA2 model with and without  $\text{Ca}^{2+}$  were similar, resembling those of the wtA2 structure.<sup>20</sup> For the unfolding of the central  $\beta$ -sheet (strands  $\beta$ 5 and  $\beta$ 4), although the force profiles were different for the wtA2 model with a higher force needed to unfold  $\beta$ 4, in the absence of  $\text{Ca}^{2+}$ , the force required for the unfolding of the central  $\beta$ -sheet in the simulations of the wtA2 model was almost the same ( $\sim 1000$  pN; Figure 2A left panel) in this study as in the previous report.<sup>20</sup> Intriguingly, when  $\text{Ca}^{2+}$  was bound, the force significantly increased to 1250 pN for the unfolding of strand  $\beta$ 4 (Figure 2A right panel), indicating that the interplay between  $\text{Ca}^{2+}$  and the involved residues at the metal-binding site impedes the unfolding of the A2 domain, in particular the detachment of  $\beta$ 4 from the remaining protein core. Therefore, binding of  $\text{Ca}^{2+}$  renders A2 more resistant against pulling forces such as those present in the shear flow of blood.

When  $\text{Ca}^{2+}$  was bound, the trajectories of the unfolding of the  $\beta$ 4 strand were also different, with the force peak being split into 3 subpeaks representing breakage of interstrand interactions within the central  $\beta$ -sheet, the associated movement of the central  $\beta$ -sheet, and the stepwise disruption of the  $\text{Ca}^{2+}$ -binding site. At the beginning, Asn1602 was pulled away from the  $\text{Ca}^{2+}$ -binding site, followed by the movement of  $\beta$ 4 (Figure 2B snapshots I and II). After the second subpeak, the  $\text{Ca}^{2+}$  ion was only coordinated by Asp1596 and Asp1498 (Figure 2B snapshot III). Finally, the



**Figure 2. Force-probe MD simulations of a wtA2 model with or without a  $\text{Ca}^{2+}$  bound at the metal-binding site.** (A) Force profiles of force-probe MD simulations of the wtA2 model. The  $\alpha$ 3- $\beta$ 4 region adopts a loop conformation with or without a  $\text{Ca}^{2+}$  ion bound at the site equivalent to the  $\text{Ca}^{2+}$ -binding site of ssA2. The  $\text{Ca}^{2+}$  ion is replaced with a water molecule (left panel) or kept at the binding site (right panel). (B) Selected snapshots of the trajectory of force-probe MD simulations of the wtA2 model bound with a  $\text{Ca}^{2+}$  ion. For the A2 domain, the  $\alpha$ -helices are colored in pink, the  $\beta$  strands in yellow, and the  $\alpha$ 3- $\beta$ 4 loop in cyan. The  $\beta$ 4 strand is marked. The residues that participate in the formation of the  $\text{Ca}^{2+}$ -binding site are shown as ball-and-stick models and labeled. The bound  $\text{Ca}^{2+}$  is shown as a golden sphere.



**Figure 3. Effect of Ca<sup>2+</sup> binding on A2 cleavage by ADAMTS13.** (A) Examination of the protective effect of Ca<sup>2+</sup> with 2-step ADAMTS13 cleavage assays. In step I, the wtA2 protein was denatured under different urea concentrations and Ca<sup>2+</sup> was supplemented as indicated. In step II, the Ca<sup>2+</sup> concentration was adjusted to 2.5mM. The cleaved and intact A2 proteins were detected with Western blotting using the specific antibodies. (B) Examination of the effect of Ca<sup>2+</sup> on the proteolysis of the GST-VWF73 proteins by ADAMTS13. No urea was added in step I. (C) Examination of the effect of Ca<sup>2+</sup> on the proteolysis of the wtA2 protein by ADAMTS13 without adjustment of the Ca<sup>2+</sup> concentration in step II. (D) Examination of the effect of Ca<sup>2+</sup> ion on the proteolysis of wtA2 by ADAMTS13 with 1-step assays.

Ca<sup>2+</sup>-binding site was demolished and  $\beta 4$  was completely unfolded (Figure 2B snapshot IV).

#### Ca<sup>2+</sup> binding protects A2 from cleavage by ADAMTS13

Because unfolding of the A2 domain is essential for the cleavage of VWF by ADAMTS13, we reasoned that the binding of Ca<sup>2+</sup> would have an impact on VWF cleavage. This hypothesis was examined using *in vitro* biochemical assays that included pretreatment of the A2 substrate with urea to facilitate the unfolding process (step I), followed by the proteolysis of A2 by ADAMTS13 (step II) using the wtA2 proteins expressed in HEK293S GNT1<sup>-</sup> cells with glycosylation (see "Discussion") but not the engineered ssA2 proteins as substrates. To investigate the effect of Ca<sup>2+</sup> on the unfolding process only, various concentrations of Ca<sup>2+</sup> (0mM, 2.5mM, and 5.0mM) were added at step I, whereas the Ca<sup>2+</sup> concentration was adjusted to the same (2.5mM which is within the normal range of blood Ca<sup>2+</sup> concentration) at step II. As shown in Figure 3A, in the presence of high concentration of urea, the wtA2 protein was cleaved by ADAMTS13; however, supplementation of Ca<sup>2+</sup> at the concentration of either 2.5mM or 5.0mM during step I significantly suppressed the process, indicating that Ca<sup>2+</sup> binding indeed impedes the unfolding of wtA2 and consequently its cleavage by ADAMTS13 (Figure 3A).

Conversely, if Ca<sup>2+</sup> exerts a protective function via the Ca<sup>2+</sup>-binding site, then the disruption or lack of the Ca<sup>2+</sup>-binding site would abolish the protective role of Ca<sup>2+</sup>. VWF73 (corresponding to residues Asp1596-Arg1668 of the A2 domain) is the minimal substrate of ADAMTS13 that is presumably unfolded and susceptible to the cleavage by ADAMTS13 without shear stress or chaotropic agents.<sup>22</sup> VWF73 supposedly does not have a Ca<sup>2+</sup>-binding site because of the absence of both Asp1498 and a defined structure. Consistently, pretreatment of VWF73 with Ca<sup>2+</sup> had no effect on the cleavage of this fragment (Figure 3B), indicating the necessity of an intact Ca<sup>2+</sup>-binding site for the protection of VWF by Ca<sup>2+</sup> from ADAMTS13 cleavage.

The metalloprotease ADAMTS13 requires Zn<sup>2+</sup><sup>33</sup> or Ca<sup>2+</sup><sup>7,14</sup> for its activity, and it has been reported that the activity of ADAMTS13 is enhanced approximately 160-fold at 5 $\mu$ M Ca<sup>2+</sup><sup>34</sup>. Therefore, Ca<sup>2+</sup> may have 2 opposing effects on VWF cleavage: stabilization of the A2 domain and enhancement of the enzymatic activity of ADAMTS13. Given that the physiologic concentration


of Ca<sup>2+</sup> remained stable, this combined effect of Ca<sup>2+</sup> was examined with the Ca<sup>2+</sup> concentration kept unchanged during step I (corresponding to the unfolding process) and step II (corresponding to the proteolytic process). The results shown in Figure 3C show a similar trend as observed in Figure 3A, again demonstrating that the presence of Ca<sup>2+</sup> leads to decreased susceptibility of the VWF A2 domain. Considering that the VWF unfolding and ADAMTS13 cleavage occur in the same environment *in vivo*, the A2 cleavage assay was further modified so that step I and step II were no longer separated, and the A2 unfolding and ADAMTS13 cleavage were carried out under the same conditions (Figure 3D). The results were very similar to those presented in Figure 3C, supporting a protective role of Ca<sup>2+</sup> in VWF proteolysis.

#### Mutations at the Ca<sup>2+</sup>-binding site impair the protective effect of Ca<sup>2+</sup> on A2 cleavage

To further investigate the functional role of Ca<sup>2+</sup> binding in the protection of the A2 domain, the wtA2 mutants D1596A, D1498A, R1597W, and N1602A, which carry point mutations of the key residues at the Ca<sup>2+</sup>-binding site, were analyzed with *in vitro* cleavage assays. At all 3 urea concentrations examined, the cleavage of the D1596A mutant appeared to be independent of the Ca<sup>2+</sup> concentration, implying that the side-chain carboxyl is required for exertion of the protective function of Ca<sup>2+</sup> binding (Figure 4A). This finding agrees with the critical role of Asp1596 shown by the structural investigations on ssA2 and its D1596A mutant.

The rest of the mutants were examined with 2-step ADAMTS13 cleavage assays with a fixed urea concentration (2.56M) in step I. The D1498A mutant showed a dramatically increased susceptibility to ADAMTS13, and the presence of a high Ca<sup>2+</sup> concentration had no effect on the protection of the A2 unfolding in step I (Figure 4B). In addition to its participation in the formation of the Ca<sup>2+</sup>-binding site, the side-chain carboxyl group of Asp1498 forms a salt bridge with the side-chain amino group of Arg1597, which stabilizes the position of Arg1597. Therefore, mutation of Asp1498 to Ala might lead to instability of this region, which probably facilitates the unfolding of the A2 domain, partially explaining the substantially increased susceptibility of this mutant. The type 2A VWD-associated R1597W mutant showed similar levels of susceptibility to ADAMTS13 in the presence and absence of Ca<sup>2+</sup> in step I

**Figure 4. Effect of mutations at the Ca<sup>2+</sup>-binding site on A2 cleavage by ADAMTS13.** (A) Examination of the effect of the D1596A mutation on Ca<sup>2+</sup> protection of A2. In step I, the D1596A mutant A2 was denatured under different urea concentrations and Ca<sup>2+</sup> was supplemented as indicated. In step II, the Ca<sup>2+</sup> concentration was adjusted to 2.5mM. The cleaved and intact proteins were detected with Western blotting using the specific antibodies. (B) Examination of the effect of the D1498A, R1597W, and N1602A mutations on Ca<sup>2+</sup> protection of A2. In step I, 2.56M urea was added. (C) Examination of the effect of the D1498A, R1597W, and N1602A mutations on the proteolysis of GST-VWF73 by ADAMTS13. No urea was added in step I and the Ca<sup>2+</sup> concentration was 2.5mM in both steps.



(Figure 4B), indicating that Ca<sup>2+</sup> protection of A2 cleavage is abolished by the R1597W mutation. Such an effect might have resulted from a change in the configuration of its main-chain carbonyl due to the introduction of a bulky side chain and the loss of the salt-bridging interaction with Asp1498 and the consequent loss or decrease of coordination with Ca<sup>2+</sup>. Intriguingly, the N1602A mutation led to resistance of A2 to the digestion by ADAMTS13 (Figure 4B).

The mutations D1596A, N1602A, and R1597W were also investigated for the ADAMTS13 minimal substrate VWF73. As expected, mutations D1596A and R1597W exhibited no effect on the susceptibility of VWF73 to ADAMTS13 proteolysis (Figure 4C). Mutation N1602A also led to resistance of the VWF73 fragment to the proteolysis (Figure 4C), although the protective effect of Ca<sup>2+</sup> might have been lost due to the disruption of the Ca<sup>2+</sup>-binding site by the N1602A mutation. It has been shown that the range of the recognized cleavage site for ADAMTS13 encompasses residues Arg1597-Ile1623.<sup>35</sup> Our results indicate a critical role of Asn1602 for cleavage of VWF by ADAMTS13, probably because of its proximity to the cleavage site of Tyr1605-Met1606. The detailed functional role(s) of Asn1602 needs to be investigated further.

## Discussion

Using structural, computational, and biochemical data, we reveal a novel Ca<sup>2+</sup>-binding site at the A2 domain of VWF and show that Ca<sup>2+</sup> binding at this site protects its unfolding and subsequent proteolysis by ADAMTS13. The VWF A2 domain shares structural similarities with other VWF A domains.<sup>25,36,37</sup> Although binding of metal ions has been reported in VWF A domains,<sup>37</sup> this is the first time that a metal-binding site has been observed in the A domains

of VWF, which is different from the metal-binding site of other VWF A domains.

Comparison of the equivalent sites in the ssA2 and wtA2 structures showed that one major difference lies in the position and configuration of Asp1596 (Figure 1C-D). In the ssA2 structure, Asp1596 is located in the  $\alpha$ 3- $\beta$ 4 loop and points its side chain inside to coordinate the bound Ca<sup>2+</sup> ion, whereas in the wtA2 structure, Asp1596 resides in the  $3_{10}$  helix and the side chain points away from the tentative Ca<sup>2+</sup>-binding site.<sup>38</sup> Despite these differences, a molecule was also detected at the site in the wtA2 structure equivalent to the Ca<sup>2+</sup>-binding site of ssA2, forming 6 coordination bonds with the surrounding residues and water molecules in a geometry similar to that in our ssA2 structure. However, the bond lengths were much longer than those in the ssA2 structure (2.7-3.3 Å vs 2.3-2.4 Å). Intriguingly, in the D1596A mutant of ssA2, with loss of the coordination of Asp1596, the Ca<sup>2+</sup>-binding site was partially assembled as in the wtA2 structure, and similarly, a molecule was bound with longer bond lengths (2.5-2.9 Å). Because this molecule is not a Ca<sup>2+</sup> ion based on the anomalous dispersion results, by analogy, the molecule bound at the same position of wtA2 was unlikely to be a Ca<sup>2+</sup> ion, implying that the partially assembled site is insufficient for Ca<sup>2+</sup> binding. Glycosylation of wtA2 occurs at Gln1515 and Gln1574 of the A2 domain of VWF, and mutation of Gln1574, which prevents its glycosylation, leads to increased susceptibility of VWF and VWF A2 to ADAMTS13 proteolysis.<sup>39</sup> Indeed, in the wtA2 structure, N-linked glycans were observed at Gln1515 and Gly1574. The glycosylation sites and the Ca<sup>2+</sup>-binding site were located on opposite sides of the A2 domain, and therefore it is unlikely that glycosylation affected the assembly of the Ca<sup>2+</sup>-binding site (supplemental Figure 3).

To investigate whether the differences in the conformation of the  $\alpha$ 3- $\beta$ 4 region and  $\text{Ca}^{2+}$  binding between the wtA2 and ssA2 structures were due to the different crystallization conditions, we explored the possibilities of obtaining a wtA2 structure with an ssA2 structure without a  $\text{Ca}^{2+}$  ion being bound. Attempts to grow crystals of wtA2 under the crystallization conditions reported here and crystals of ssA2 under the conditions reported by Zhang et al<sup>21</sup> were unsuccessful. Instead, we obtained crystals of wtA2 from both the cocrystallization and soaking experiments under the same crystallization conditions used by Zhang et al<sup>21</sup> using supplementation of 10mM  $\text{CaCl}_2$  and crystals of the ssA2 protein treated with 10mM EDTA under the crystallization conditions reported here. No  $\text{Ca}^{2+}$  signal was detected in the anomalous dispersion diffraction data for these crystals (data not shown). In the derived wtA2 structures, the  $\alpha$ 3- $\beta$ 4 region assumed the same  $3_{10}$ -helical conformation with a molecule bound at the metal-binding site in a way similar to that in the wtA2 structure (data not shown), indicating that the  $\alpha$ -helical conformation of the  $\alpha$ 3- $\beta$ 4 region and the incapability of binding a  $\text{Ca}^{2+}$  are intrinsic properties of the wtA2 structure under the corresponding crystallization conditions. Conversely, in the structure of EDTA-treated ssA2 determined at a 2.0 Å resolution, the  $\text{Ca}^{2+}$ -binding site was almost identical to that in the structure of ssA2 in complex with  $\text{Ca}^{2+}$  (supplemental Figure 2B), although no  $\text{Ca}^{2+}$  was bound, implicating that the formation of the binding site in ssA2 is not induced by  $\text{Ca}^{2+}$ , but rather occurs naturally under the crystallization conditions.

These results indicate that the loop conformation of the  $\alpha$ 3- $\beta$ 4 region and the capability of binding a  $\text{Ca}^{2+}$  are intrinsic properties of the ssA2 structure under the crystallization conditions reported in this study, and that the observed differences between the wtA2 and ssA2 structures might result from the different crystallization conditions. Analysis of the crystal packing of the 2 crystal forms revealed that the  $\alpha$ 3- $\beta$ 4 region is exposed on the solvent-accessible surface in both structures and is engaged in the interactions with the symmetry-related molecules in the wtA2 (supplemental Figure 4A) but not the ssA2 structure. Moreover, superposition of the ssA2 structure onto the wtA2 structure showed that in the crystal packing of wtA2, the  $\alpha$ 3- $\beta$ 4 region of the ssA2 would clash with the symmetry-related molecule (supplemental Figure 4B). Therefore, the crystal packing in the wtA2 structure hinders the  $\alpha$ 3- $\beta$ 4 region from forming a loop structure and therefore prevents complete assembly of the  $\text{Ca}^{2+}$ -binding site. In solution, it is plausible that the  $\alpha$ 3- $\beta$ 4 region of VWF A2 might have a high flexibility with the  $3_{10}$ -helical conformation seen in the wtA2 structure and the loop conformation seen in the ssA2 structure as 2 quasi-stable conformations, which have been independently captured under different crystallization conditions.

It was reported recently that there is an intermediate unfolded state of A2 that shows unfolding of the C-terminal region up to the  $\beta$ 4 strand.<sup>19</sup> Of the 5 residues involved in the formation of the  $\text{Ca}^{2+}$ -binding site identified in this study, 4 (Asp1596, Arg1597, Ala1600, and Asn1602) were located in the C-terminal region of the  $\alpha$ 3- $\beta$ 4 loop that immediately flanks the  $\beta$ 4 strand (supplemental Figure 5). Based on the crystal structure of the catalytic domain

of ADAMTS5,<sup>40</sup> we constructed a model of ADAMTS13 showing that the active site of the enzyme is a narrow and deep groove (unpublished data), suggesting that the  $\beta$ 4 strand needs to be displaced and inserted into the groove for ADAMTS13 cleavage. The displacement of the  $\beta$ 4 strand would require a conformational change of the  $\alpha$ 3- $\beta$ 4 loop and very likely the disruption of the  $\text{Ca}^{2+}$ -binding site as well, which implies that  $\text{Ca}^{2+}$  exerts its protective role through stabilization of the  $\alpha$ 3- $\beta$ 4 loop and thus restraint of the  $\beta$ 4 strand.

#### PDB accession codes

The structures of ssA2 and its D1596A, N1602A, and D1596A/N1602A mutants have been deposited with the RCSB PDB under accession codes 3PPV, 3PPW, 3PPX, and 3PPY, respectively.

#### Acknowledgments

We thank the staff members at the Shanghai Synchrotron Radiation Facility (Shanghai, China) for technical support in diffraction data collection and Professors Xiaohui Zhang (Department of Mechanical Engineering and Mechanics, Lehigh University), Jianfeng Chen (Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China), and Reinhard Schneppenheim (Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany) for inspiring discussions.

This work was supported by grants from the Ministry of Science and Technology of China (2007CB914302 and 2011CB966301), the National Natural Science Foundation of China (30730028), the Chinese Academy of Sciences (KSCX2-YW-R-107 and SIBS2008002), and the Klaus Tschira foundation. C.B. is grateful for a Feodor Lynen fellowship from the Alexander von Humboldt Foundation.

#### Authorship

Contribution: M.Z. and X.D. carried out the structural and biochemical studies and drafted the manuscript; C.B. and F.G. conceived the MD simulation studies; C.B. carried out the MD simulation studies and participated in the drafting of the manuscript; H.C. and X.L. participated in the biochemical studies; Y.Z. and T.A.S. provided the initial wtA2 domain sample and crystals; C.Z. participated in the data analysis and drafting of the manuscript; and J.D. conceived of the study, participated in the experimental design and coordination, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation of C.B. is Fritz-Haber-Institut der Max-Planck-Gesellschaft, Theory Department, Berlin-Dahlem, Germany.

Correspondence: Dr Jianping Ding, 320 Yue-Yang Rd, Shanghai 200031, China; e-mail: [jpding@sibs.ac.cn](mailto:jpding@sibs.ac.cn).

#### References

- Sadler JE. Biochemistry and genetics of von Willebrand factor. *Annu Rev Biochem*. 1998;67:395-424.
- Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. *Haemophilia*. 2008; 14(suppl 5):11-26.
- Ruggeri ZM. Structure and function of von Willebrand factor. *Thromb Haemost*. 1999;82(2):576-584.
- Sadler JE. von Willebrand factor: two sides of a coin. *J Thromb Haemost*. 2005;3(8):1702-1709.
- Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature*. 2001;413(6855):488-494.
- Battle J, Lopez-Fernandez MF, Lopez-Botrasca A, et al. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. *Blood*. 1987;70(1):173-176.
- Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. *Blood*. 1996;87(10):4223-4234.

8. Sadler JE. A new name in thrombosis, ADAMTS13. *Proc Natl Acad Sci U S A*. 2002;99(18):11552-11554.
9. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. *Proc Natl Acad Sci U S A*. 1990;87(16):6306-6310.
10. Sutherland JJ, O'Brien LA, Lillcrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. *J Mol Model*. 2004;10(4):259-270.
11. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. *Blood*. 1994;83(8):2171-2179.
12. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. *Proc Natl Acad Sci U S A*. 2007;104(19):7899-7903.
13. Furlan M. Von Willebrand factor: molecular size and functional activity. *Ann Hematol*. 1996;72(6):341-348.
14. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. *Blood*. 1996;87(10):4235-4244.
15. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. *Blood*. 2002;100(12):4033-4039.
16. Tsai HM. Shear stress and von Willebrand factor in health and disease. *Semin Thromb Hemost*. 2003;29(5):479-488.
17. Sadler JE. New concepts in von Willebrand disease. *Annu Rev Med*. 2005;56:173-191.
18. Hassenpflug WA, Budde U, Obser T, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. *Blood*. 2006;107(6):2339-2345.
19. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. *Science*. 2009;324(5932):1330-1334.
20. Baldauf C, Schneppenheim R, Stacklies W, et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. *J Thromb Haemost*. 2009;7(12):2096-2105.
21. Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. *Proc Natl Acad Sci U S A*. 2009;106(23):9226-9231.
22. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. *Blood*. 2004;103(2):607-612.
23. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Abelson JN, Simon MI, Carter CW Jr, Sweet RM, eds. *Methods in Enzymology, Volume 276: Macromolecular Crystallography, Part A*. San Diego: Academic Press; 1997:307-326.
24. McCoy AJ. Solving structures of protein complexes by molecular replacement with Phaser. *Acta Crystallogr D Biol Crystallogr*. 2007;63(pt 1):32-41.
25. Huizinga EG, Martijn van der Plas R, Kroon J, Sixma JJ, Gros P. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. *Structure*. 1997;5(9):1147-1156.
26. Brünger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr*. 1998;54(pt 5):905-921.
27. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr*. 2004;60(pt 12):2126-2132.
28. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr*. 1997;53(pt 3):240-255.
29. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. *J Comput Chem*. 2005;26(16):1701-1718.
30. Jorgensen WL, Ulmschneider JP, Tirado-Rives J. Free energies of hydration from a generalized Born model and an ALL-atom force field. *J Phys Chem B*. 2004;108:16264-16270.
31. Lawrence CP, Skinner JL. Flexible TIP4P model for molecular dynamics simulation of liquid water. *Chem Phys Lett*. 2003;372(5-6):842-847.
32. Harding MM. Geometry of metal-ligand interactions in proteins. *Acta Crystallogr D Biol Crystallogr*. 2001;57(pt 3):401-411.
33. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. *Blood*. 1997;89(6):1954-1962.
34. Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. *J Biol Chem*. 2006;281(2):850-857.
35. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. *Blood*. 2008;112(5):1713-1719.
36. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. *J Biol Chem*. 1998;273(17):10396-10401.
37. Springer TA. Complement and the multifaceted functions of VWA and integrin I domains. *Structure*. 2006;14(11):1611-1616.
38. Harding MM. Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. *Acta Crystallogr D Biol Crystallogr*. 2002;58(pt 5):872-874.
39. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. *Blood*. 2008;111(6):3042-3049.
40. Mosyak L, Georgiadis K, Shane T, et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. *Protein Sci*. 2008;17(1):16-21.